Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. van Rhee F, et al. Among authors: casper c. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. van Rhee F, et al. Among authors: casper c. J Clin Oncol. 2010 Aug 10;28(23):3701-8. doi: 10.1200/JCO.2009.27.2377. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625121 Clinical Trial.
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. Kurzrock R, et al. Among authors: casper c. Clin Cancer Res. 2013 Jul 1;19(13):3659-70. doi: 10.1158/1078-0432.CCR-12-3349. Epub 2013 May 9. Clin Cancer Res. 2013. PMID: 23659971 Clinical Trial.
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres.
Robinson D Jr, Reynolds M, Casper C, Dispenzieri A, Vermeulen J, Payne K, Schramm J, Ristow K, Desrosiers MP, Yeomans K, Teltsch D, Swain R, Habermann TM, Rotella P, Van de Velde H. Robinson D Jr, et al. Among authors: casper c. Br J Haematol. 2014 Apr;165(1):39-48. doi: 10.1111/bjh.12717. Epub 2014 Jan 6. Br J Haematol. 2014. PMID: 24387011 Free article.
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, Bandekar R, Hall B, van de Velde H, Vermeulen J, Reddy M, van Rhee F. Casper C, et al. Clin Cancer Res. 2015 Oct 1;21(19):4294-304. doi: 10.1158/1078-0432.CCR-15-0134. Epub 2015 Jun 29. Clin Cancer Res. 2015. PMID: 26124203 Clinical Trial.
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. van Rhee F, et al. Among authors: casper c. Oncotarget. 2015 Oct 6;6(30):30408-19. doi: 10.18632/oncotarget.4655. Oncotarget. 2015. PMID: 26327301 Free PMC article. Clinical Trial.
246 results